|
Found 38 result(s) FROM 1963 pages containing the term 'gout'.
Thursday Oct 22, 2009
Water, Skim Milk May Stave Off Gout Attacks
Encouraging gouty arthritis patients to drink more water and/or skim milk may lead to fewer gout attacks...
Thursday Oct 01, 2009
MRI Can Show Joint Damage in Early Gout
For patients with gout but normal plain radiographs, MRI is more sensitive than ultrasound for detecting early gout, but what to do with that information is unclear...
Tuesday Aug 04, 2009
FDA Spikes Pegloticase Gout OK
Savient Pharmaceuticals' shares tanked on the FDA's refusal to approve Krystexxa™ for gout...
Thursday Jun 25, 2009
Pegloticase Shrinks Tophi Even in Resistant Gout
Pegloticase significantly reduced tophus size in 40% of treatment-failure gout patients...
Thursday Jun 04, 2009
Allopurinol Extends Gout Survival
Gout patients who take allopurinol live longer than those who do not, mostly due to decreased cardiovascular mortality...
Monday Apr 13, 2009
Caffeine May Be New Rx for Pain-Free Exercise
Jumpstarting a workout with a jolt of java or another readily available caffeinated beverage may reduce the pain associated with exercise...
Tuesday Mar 10, 2009
Each 500 mg of Vitamin C Cuts Gout Risk by 17%
Gout risk drops significantly in men who have high dietary levels of vitamin C, and even more in those who take vitamin C supplements...
Monday Feb 16, 2009
FDA Gives Nod to Uloric® (febuxostat), First New Gout Treatment in 40 Years
The US FDA approved 40 mg and 80 mg doses of Takeda Pharmaceutical's febuxostat (Uloric) for the chronic management of hyperuricemia in patients with gout...
Thursday Dec 04, 2008
FDA Panel Okays Febuxostat for Gout
A US FDA panel voted 12-0 this week to recommend approval of Takeda Pharmaceutical's febuxostat (Uloric®), the first new gout drug in 40 years...
Wednesday Nov 12, 2008
Pegloticase Offers Hope to Patients With Worst Types of Gout
Pegloticase (Puricase®, Savient Pharmaceuticals, Inc.) performed well in two Phase III studies...
Wednesday Nov 12, 2008
Novartis’ ACZ885 Phase III Data Show Rapid, Sustained Clinical Remission in Children and Adults with CAPS, a Group of Rare, Potentially Life-Threatening Autoinflammatory Diseases
Novartis also announced that preliminary results of a phase I/II study in systemic juvenile idiopathic arthritis showed that most patients treated with ACZ885 achieved substantial clinical improvement within 15 days...
Tuesday Oct 07, 2008
Discovery Of New Genes Linked To Gout
Two new genes have been identified and associated with increased risk of elevated uric acid levels in the blood, which can lead to gout…
Monday Sep 29, 2008
Pegloticase May be Just What the Rheumatologist Ordered for Treatment-Resistant Gout
Treatment-resistant gout may have finally met its match with a new, urate-lowering drug...
Wednesday Sep 10, 2008
Arcalyst® (rilonacept) Reduced Gout Flares by 81% in a Phase II Study Initiating Urate-Lowering Therapy
Based upon these results, a phase III clinical development program will be initiated early in 2009 with Arcalyst in the prevention of gout flares in patients initiating urate-lowering drug therapy...
Tuesday Jul 22, 2008
Ardea Biosciences Advances RDEA806 Into Phase IIa Proof-of-Concept Study for Gout
Ardea Biosciences has received regulatory approval to begin a phase IIa proof-of-concept clinical trial evaluating RDEA806 in gout patients with hyperuricemia...
Tuesday Jul 08, 2008
Rheumatologists Can Expect to See More HIV-Related Joint Problems as Mortality Drops
Mortality in HIV-infected patients has dropped comparable with general population levels, especially in those who begin highly active antiretroviral therapy (HAART) early, and one result is that rheumatologists can expect to see more long-term HIV survivors with joint problems related to the underlying HIV, treatment, or aging...
Friday Feb 29, 2008
Ipsen's Adenuric® (febuxostat) for Chronic Hyperuricemia in Gout Receives Positive Opinion From CHMP; First Treatment Alternative in >40 Years if Approved by European Commission
Ipsen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) adopted a positive opinion for Adenuric® (febuxostat) to treat chronic hyperuricemia for conditions in which urate deposition has already occurred...
Monday Nov 26, 2007
Teriparatide Builds More Bone Than Alendronate in Steroid-Caused Osteoporosis
Teriparatide built more bone mass and prevented more vertebral fractures than alendronate in the first head-to-head study of the two drugs for glucocorticoid-induced osteoporosis...
Friday Nov 09, 2007
Control of Osteoclast Development Goes Awry in Gout
Patients with tophaceous gout have disordered osteoclast development partly due to the effect of uric acid crystals on bone marrow stromal cells...
Wednesday Aug 15, 2007
Successful Gout Treatment Requires Up To 33 Months to Clear Urate Crystals From Joint Fluid
Reduction of serum uric acid levels eventually clears urate crystals from the synovial fluid in patients with gout, but this may require up to 33 months of treatment in some cases...Pascual E, et al. Ann Rheum Dis. 2007;66:1056-1058.
Thursday Aug 09, 2007
Regeneron's Rilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS, a Spectrum of Rare Inherited Autoinflammatory Conditions
Regeneron Pharmaceuticals, Inc, announced that the US FDA has accepted for filing and granted priority review status to the Biologics License Application (BLA) for rilonacept (interleukin-1 (IL-1) Trap), a potent, long-acting inhibitor of IL-1, for the long-term treatment of cryopyrin-associated periodic syndromes (CAPS)...
Thursday Jul 12, 2007
Coffee Consumption Slashes Gout Risk
Coffee may stave off gout before it starts, but patients who do develop gout are likely to receive suboptimal care...
Friday Jun 15, 2007
Two Thirds of Gout Patients Receiving No, or Not Enough Treatment
A number of new treatment options for gout are available, but the major clinical problem is that even after gout diagnosis, only about one third of patients receive urate-lowering therapy...
Tuesday Mar 13, 2007
Experts Hope Ultrasound and MRI Will Get More Gout Patients Into Treatment
In-office ultrasonography and greater use of MRI might improve gout diagnosis, simplify monitoring of response to urate-lowering therapy, and inspire more aggressive use of hypouricemic agents...
Tuesday Mar 13, 2007
Less Use of Diuretics, Earlier Hypouricemic Therapy Urged In Renal Transplant Patients At Risk for Recurrent Gout
Up to 23% of renal transplant recipients develop gout posttransplant but most are not getting hypouricemic therapy, even when they report recurrent gout attacks...
Thursday Mar 01, 2007
Calcium-Containing Crystals May Contribute to OA Joint Destruction, Be Amenable to Treatment
Evidence is accumulating that calcium-containing crystals, which are common in OA synovial fluids in some patients, contribute to the development of rapidly destructive arthritis and might be a target for therapeutic intervention...
Friday Jan 12, 2007
Lavage With Steroids Better Than Aspiration With Steroids for Inflammatory Knee Arthritis
Arthroscopic lavage plus steroids provides a more prolonged therapeutic benefit than joint aspiration plus steroids or lavage alone in knee inflammatory arthritis...
Thursday Sep 14, 2006
Gout Is an Independent Risk Factor for Acute MI
New data show that gout, the most common inflammatory arthritis in the US population, is the third highest risk factor for acute MI after smoking and family history... Krishnan E, et al. Arthritis Rheum. 2006;54:2688-2696.
Monday Jun 19, 2006
EULAR Issues First Gout Guidelines in Advance of Annual Meeting
The EULAR Gout Task Force has issued a two-part set of evidence-based recommendations for the diagnosis and management of gout... Zhang W, et al. Ann Rheum Dis [serial online]; 17 May 2006.
Friday Dec 16, 2005
Novel Gout Drug Febuxostat More Effective Than Allopurinol in Lowering Urate Levels
New data from a phase III trial show that febuxostat, a next-generation nonpurine selective xanthine oxidase inhibitor and the first new agent for gout in 40 years, is significantly more effective than standard doses of allopurinol in lowering serum uric acid levels to <6.0 mg/dL... Becker MA, et al. N Engl J Med. 2005;353:2450-2461.
Friday Dec 02, 2005
New Gout Drug PEG-Uricase May Benefit Severe, Refractory Patients
A new study has found that multiple doses of PEG-uricase, a novel polyethylene glycol conjugate of porcine uricase (urate oxidase), has shown substantial and sustained reductions in plasma urate levels in patients with severe, refractory gout... Presented at: Annual Meeting of the American College of Rheumatology; November 12–17, 2005; San Diego, Calif. Abstract 1836.
Thursday Nov 17, 2005
Febuxostat Superior to Allopurinol for Hyperuricemia in Gouty Arthritis
The next-generation nonpurine selective xanthine oxidase inhibitor febuxostat, the first new agent for gout in 40 years, proved to be significantly more potent than allopurinol for lowering serum uric acid to <6.0 mg/dL, a level associated with a dissolution of the urate crystals that cause gouty arthritis and a reduction in tophus size ... Annual Meeting of the American College of Rheumatology; November 12–17, 2005; San Diego, Calif.
Friday Jun 10, 2005
EULAR Issues Treatment Recommendations for Early Arthritis, Ankylosing Spondylitis, and Gout
European rheumatologists released three new sets of recommendations for the management of early arthritis, ankylosing spondylitis (AS), and gout. Taken together the three sets of recommendations do not offer many specifics, but do chart at least an initial course of action for patients...Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Tuesday Mar 15, 2005
Trials of Gout Drug Febuxostat Demonstrate Promising Efficacy
Results of Phase II and Phase III studies of the novel xanthine oxidase inhibitor suggest that it may play an important role in treating hyperuricemic patients with renal insufficiency and allopurinol hypersensitivity...Becker MA, et al. Arthritis Rheum. 2005;52:916-923.
Thursday Nov 04, 2004
Next generation COX-2 Inhibitor Arcoxia Receives FDA Approvable Letter
Final approval of etoricoxib must await FDA review of additional safety and efficacy data... Baraf HSB, et al. Presented at: Annual Meeting of the American College of Rheumatology; San Antonio, Tex.
Wednesday Nov 03, 2004
Merck Withdraws NDA for COX-2 Inhibitor Arcoxia
Just days after receiving an FDA "approvable letter", the company has withdrawn the new drug application for etoricoxib until additional safety and efficacy data are available...
Friday Oct 22, 2004
New Drug Appears to Lower Serum Urate Levels in Gout Patients
Phase III trial reported that febuxostat reduced frequency of flares as well as gouty tophus better than allopurinol... Becker MA, et al. Presented at: Annual Meeting of the American College of Rheumatology; October 21, 2004; San Antonio, Tex.
Monday Aug 30, 2004
Incidence of Gout Increasing; New Therapies Have Promise to Make Disease More Manageable
(Bieber JD, Terkeltaub RA, et al. Arthritis Rheum. 2004;50:2400-2414.)
|
